| Literature DB >> 26019620 |
Ralitsa Georgieva1, Lyubomira Yocheva2, Lilia Tserovska2, Galina Zhelezova2, Nina Stefanova1, Akseniya Atanasova1, Antonia Danguleva1, Gergana Ivanova1, Nikolay Karapetkov1, Nevenka Rumyan1, Elena Karaivanova1.
Abstract
Antimicrobial activity and antibiotic susceptibility were tested for 23 Lactobacillus and three Bifidobacterium strains isolated from different ecological niches. Agar-well diffusion method was used to test the antagonistic effect (against Staphylococcus aureus, Escherichia coli, Bacillus cereus and Candida albicans) of acid and neutralized (pH 5.5) lyophilized concentrated supernatants (cell-free supernatant; CFS) and whey (cell-free whey fractions; CFW) from de Man-Rogosa-Sharpe/trypticase-phytone-yeast broth and skim milk. Acid CFS and CFW showed high acidification rate-dependent bacterial inhibition; five strains were active against C. albicans. Neutralized CFS/CFW assays showed six strains active against S. aureus (L. acidophilus L-1, L. brevis 1, L. fermentum 1, B. animalis subsp. lactis L-3), E. coli (L. bulgaricus 6) or B. cereus (L. plantarum 24-4В). Inhibition of two pathogens with neutralized CFS (L. bulgaricus 6, L. helveticus 3, L. plantarum 24-2L, L. fermentum 1)/CFW (L. plantarum 24-5D, L. plantarum 24-4В) was detected. Some strains maintained activity after pH neutralization, indicating presence of active substances. The antibiotics minimum inhibitory concentrations (MICs) were determined by the Epsilometer test method. All strains were susceptible to ampicillin, gentamicin, erythromycin and tetracycline. Four lactobacilli were resistant to one antibiotic (L. rhamnosus Lio 1 to streptomycin) or two antibiotics (L. acidophilus L-1 and L. brevis 1 to kanamycin and clindamycin; L. casei L-4 to clindamycin and chloramphenicol). Vancomycin MICs > 256 μg/mL indicated intrinsic resistance for all heterofermentative lactobacilli. The antimicrobially active strains do not cause concerns about antibiotic resistance transfer and could be used as natural biopreservatives in food and therapeutic formulations.Entities:
Keywords: MIC; antagonistic effect; lactic acid bacteria
Year: 2014 PMID: 26019620 PMCID: PMC4434095 DOI: 10.1080/13102818.2014.987450
Source DB: PubMed Journal: Biotechnol Biotechnol Equip ISSN: 1310-2818 Impact factor: 1.632
Lactobacillus and Bifidobacterium strains included in this study and source of isolation.
| Strain | Source of isolation |
|---|---|
| Home-made yoghurt | |
| Home-made cheese | |
| Yellow cheese whey | |
| Plant origin-melon | |
| Blue-green algae | |
| Pickle | |
| Raw-fermented sausages | |
| Baby faeces | |
| Saliva |
Figure 1. Antimicrobial activity of Lactobacillus and Bifidobacterium strains against Staphylococcus aureus NBIMCC 3703: (A) aCFS and nCFS; (B) aCFW and nCFW. *pH values of acid CFSs and acid CFWs.
Figure 2. Antimicrobial activity of Lactobacillus and Bifidobacterium strains against Bacillus cereus NBIMCC 1085: (A) aCFS and nCFS; (B) aCFW and nCFW. *pH values of acid CFSs and acid CFWs.
Figure 3. Antimicrobial activity of Lactobacillus and Bifidobacterium strains against Escherichia coli NBIMCC 3702: (A) aCFS and nCFS; (B) aCFW and nCFW. *pH values of acid CFSs and acid CFWs.
MIC (μg/mL) of antimicrobials for Lactobacillus and Bifidobacterium strains determined by E-test®.
| Susceptibility to the following antibiotic MIC (μg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tested strain | AM | VM | GM | KM | SM | EM | CM | TC | CL |
| EFSA | |||||||||
| 0.125 | 1 | 12 | >256R | 6 | 0.75 | 4R | 0.75 | 1.5 | |
| 0.19 | 0.19 | 0.25 | 8 | 0.50 | 0.032 | 0.19 | 0.75 | 1.5 | |
| EFSA | |||||||||
| 1 | 0.50 | 2 | 4 | 6 | 0.25 | 0.50 | 1 | 3 | |
| 0.094 | 0.094 | 1.5 | 12 | 0.50 | 0.064 | 0.125 | 1 | 2 | |
| 0.047 | 0.094 | 0.094 | 12 | 0.50 | 0.064 | 0.19 | 0.19 | 2 | |
| 0.032 | 0.38 | 0.75 | 12 | 0.75 | 0.023 | 0.50 | 0.75 | 0.032 | |
| 0.023 | 1 | 2 | 16 | 4 | 0.50 | 0.75 | 1 | 2 | |
| 0.19 | 0.25 | 0.75 | 6 | 12 | <0.016 | 0.032 | 0.125 | 4 | |
| 0.023 | 0.38 | 1 | 8 | 4 | <0.016 | 0.023 | 0.50 | 4 | |
| 0.047 | 0.38 | 0.75 | 6 | 4 | < 0.016 | 0.023 | 0.50 | 3 | |
| 0.064 | 0.75 | 1.5 | 6 | 4 | <0.016 | 0.016 | 0.50 | 3 | |
| 0.125 | 0.38 | 1 | 8 | 6 | < 0.016 | 0.023 | 0.25 | 4 | |
| 0.094 | 0.25 | 2 | 12 | 12 | <0.016 | 0.047 | 0.75 | 0.094 | |
| EFSA | n.r. | ||||||||
| 0.19 | >256 | <0.016 | 12 | 4 | 0.19 | 2R | 1 | 8R | |
| 0.50 | >256 | 0.19 | 32 | 32 | 0.125 | <0.016 | <0.016 | 3 | |
| EFSA | n.r. | ||||||||
| 0.75 | >256 | 0.75 | 12 | >1024R | 1 | 0.75 | 0.50 | 4 | |
| 0.19 | >256 | <0.016 | 4 | 4 | 0.023 | 0.19 | 0.19 | 3 | |
| EFSA | n.r. | n.r. | |||||||
| 0.38 | >256 | 3 | 32 | 24 | 0.75 | 2 | 16 | 4 | |
| 0.75 | >256 | 4 | 48 | 32 | 1 | 2 | 24 | 4 | |
| 1 | >256 | 4 | 48 | 64 | 0.75 | 0.75 | 24 | 6 | |
| 0.75 | >256 | 3 | 48 | 48 | 0.75 | 1 | 16 | 4 | |
| EFSA | n.r. | ||||||||
| 0.38 | >256 | 2 | 64R | 16 | 0.19 | 12R | 6 | 4 | |
| 0.023 | >256 | 0.38 | 12 | 4 | 0.38 | <0.016 | 0.38 | 1.5 | |
| EFSA | n.r. | ||||||||
| <0.016 | 0.50 | 2 | 12 | 2 | 0.023 | 0.023 | 1 | 3 | |
| <0.016 | 0.38 | 2 | 8 | 2 | 0.023 | 0.023 | 0.75 | 2 | |
| 0.047 | 0.75 | 3 | 12 | 4 | 0.064 | 0.50 | 1 | 3 | |
Note: AM – ampicillin, VM – vancomycin, GM – gentamicin, KM – kanamycin, SM – streptomycin, EM – erythromycin, CM – clindamycin, TC – tetracycline, CL – chloramphenicol.
*Strains with MIC higher than the breakpoints are considered as resistant (R) according to EFSA.[4].
n.r. – not required.
The bold values are reference values given by EFSA. [4] and that is why they are visually emphasized. This would allow easier comparison with the values obtained for the tested strains.